Alcobra Provides Update on Recent FDA Meeting and Path Forward for MDX Clinical Development Program
Jan 09, 2017 12:01 pm UTC| Business
- Alcobra and FDA agree on review of available data from the Phase 3 MEASURE study in a future NDA submission- Top-line results from the MEASURE study to be reported in the coming weeks- FDA to modify Clinical Hold from...
Jan 09, 2017 12:01 pm UTC| Business
BRISBANE, Calif., Jan. 09, 2017 -- Cutera, Inc. (NASDAQ:CUTR) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, today announced the following...
VBL Therapeutics Provides Year End 2016 Corporate Update
Jan 09, 2017 12:01 pm UTC| Business
TEL AVIV, Israel, Jan. 09, 2017 -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017. Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to...
Natus Medical Announces 2017 Annual and First Quarter Financial Guidance
Jan 09, 2017 12:01 pm UTC| Business
Updates Fourth Quarter 2016 RevenueAnnounces Fourth Quarter 2016 Financial Results Conference Call Date PLEASANTON, Calif., Jan. 09, 2017 -- Natus Medical Incorporated (NASDAQ:BABY) today announced its financial...
Noble Energy Closes Delaware Basin Acquisitions Totaling 7,200 Net Acres
Jan 09, 2017 12:01 pm UTC| Business
Houston, Jan. 09, 2017 -- Noble Energy, Inc. (NYSE: NBL) (“Noble Energy” or “the Company”) today announced that the Company has finalized the previously announced bolt-on transactions which have added approximately...
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2016 Revenue
Jan 09, 2017 12:01 pm UTC| Business
Q4 Revenue will be at least $11.3 million, representing 45% growth over prior year 2016 Revenue will be at least $41.0 million, representing 50% growth over prior year ALACHUA, Fla., Jan. 09, 2017 -- AxoGen, Inc....
Jan 09, 2017 12:01 pm UTC| Business
Critical Phase 3 study design input received from U.S. Food and Drug Administration (“FDA”): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator intramuscular (“IM”) arm...